New 6-Month TB drug cocktail could replace Year-Long ordeal
NCT ID NCT07486024
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new 6-month treatment called BPaLM for people with multidrug-resistant tuberculosis (MDR-TB). The goal is to see if it works as well as the current 18+ month regimen. About 55 adults in France will receive the shorter treatment, and their outcomes will be compared to past patients who had standard care. If effective, this could greatly reduce treatment burden and improve quality of life for MDR-TB patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin)
- What this could lead to
- If successful, this could offer a much shorter, more tolerable treatment for multidrug-resistant tuberculosis, replacing the current long and difficult regimen.
- What could go wrong
- This is a small, non-randomized trial comparing to historical data, so results may not be conclusive. The regimen still requires careful monitoring for side effects like nerve damage or heart issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBIOTIC RESISTANCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pitié-Salpêtrière Hospital - infectious and tropical diseases
Paris, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new antibiotic combo beat Drug-Resistant urinary infections in the blood?
- Superbug sleuths decode the DNA of drug-resistant e. coli to stop its spread
- Old heart drug takes on superbugs in cancer patients
- Hidden TB risks: study links diet, diabetes, and parasites to latent infection
- Smart dosing could make MDR-TB treatment safer
- New hope against Drug-Resistant TB: phase II trial launches